Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 14/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7984031 | 0.78 | UHRF1 (0.37) | CYP3A4AR | |
| SCHEMBL3372231 | 0.77 | PPARA (0.49) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL3371452 | 0.75 | PPARA (0.61) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL1549824 | 0.75 | FBP1 (0.58) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL22005942 | 0.73 | FBP1 (0.57) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL2431952 | 0.73 | FBP1 (0.62) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL941712 | 0.73 | FBP1 (0.57) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL7984260 | 0.73 | TSHR (0.64) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL9701146 | 0.73 | FBP1 (0.57) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL21991780 | 0.73 | TSHR (0.51) | FBP1PPARAABCB11CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | FBP1 3086/4885PPARA 455/4885ABCB11 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.